Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2020, which ended October 25, 2019....
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced the approval of the Axonics r-SNM System...
Nuvectra Corporation (NASDAQ: NVTR) , a neurostimulation medical device company, today announced that it has elected to file a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the Eastern District of Texas (the “Court”). ...
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2019....
SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2019....
Medtronic plc (NYSE:MDT) today announced results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study showing that an investigational set of algorithms in the Micra Transcatheter Pacing System (TPS) significantly improves synchrony and cardiac function in patients with impaired electrical conduction between the chambers of the heart...
Stereotaxis (NYSE American: STXS) and Catheter Precision today announced the first patients have been successfully treated with the integration of Catheter Precision’s VIVO arrhythmia localization and Stereotaxis’ Robotic Magnetic Navigation technologies....
Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell patient-specific arthroplasty joint replacement implants designed to fit each patient’s unique ...
Nevro (NYSE: NVRO) is up 24% after announcing a monster third quarter earnings report and also increasing their financial guidance for worldwide revenue in 2019....
Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for the Senza Omnia Spinal Cord Stimulation (SCS) System...